Three-Dimensional Reconstructed Bone Marrow Matrix Culture Improves the Viability of Primary Myeloma Cells In-Vitro via a STAT3-Dependent Mechanism.
ADP-ribosyl Cyclase 1
/ biosynthesis
Aged
Bone Marrow
/ pathology
Cell Culture Techniques
Cell Proliferation
Cell Survival
Cells, Cultured
Cyclic S-Oxides
/ pharmacology
Female
Fluoresceins
/ pharmacology
Humans
In Vitro Techniques
Leukocytes, Mononuclear
/ cytology
Male
Membrane Glycoproteins
/ biosynthesis
Middle Aged
Multiple Myeloma
/ immunology
STAT3 Transcription Factor
/ metabolism
Succinimides
/ pharmacology
3D culture
STAT3
primary myeloma cells
Journal
Current issues in molecular biology
ISSN: 1467-3045
Titre abrégé: Curr Issues Mol Biol
Pays: Switzerland
ID NLM: 100931761
Informations de publication
Date de publication:
08 Jun 2021
08 Jun 2021
Historique:
received:
10
05
2021
revised:
04
06
2021
accepted:
04
06
2021
entrez:
2
7
2021
pubmed:
3
7
2021
medline:
21
12
2021
Statut:
epublish
Résumé
Primary myeloma (PM) cells are short-lived in conventional culture, which limited their usefulness as a study model. Here, we evaluated if three-dimensional (3D) culture can significantly prolong the longevity of PM cells in-vitro. We employed a previously established 3D model for culture of bone marrow mononuclear cells isolated from 15 patients. We assessed the proportion of PM cells, viability and proliferation using CD38 staining, trypan blue exclusion assays and carboxy fluorescein succinimidyl ester (CFSE) staining, respectively. We observed significantly more CD38+ viable cells in 3D than in conventional culture (65% vs. 25%,
Identifiants
pubmed: 34201211
pii: cimb43010026
doi: 10.3390/cimb43010026
pmc: PMC8928965
doi:
Substances chimiques
5-(6)-carboxyfluorescein diacetate succinimidyl ester
0
Cyclic S-Oxides
0
Fluoresceins
0
Membrane Glycoproteins
0
STAT3 Transcription Factor
0
STAT3 protein, human
0
Succinimides
0
stattic
0
CD38 protein, human
EC 3.2.2.5
ADP-ribosyl Cyclase 1
EC 3.2.2.6
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
313-323Références
Int J Pharm. 2008 Jan 22;347(1-2):118-27
pubmed: 17681440
Cancers (Basel). 2019 May 26;11(5):
pubmed: 31130718
Blood. 2015 May 14;125(20):3049-58
pubmed: 25838343
Immunity. 1999 Jan;10(1):105-15
pubmed: 10023775
Int J Cancer. 1999 Nov 12;83(4):555-63
pubmed: 10508494
Exp Hematol. 2007 Oct;35(10):1550-61
pubmed: 17889722
Mol Cancer Res. 2008 Jan;6(1):21-30
pubmed: 18184972
Oncotarget. 2018 Nov 13;9(89):36048
pubmed: 30542518
Neoplasia. 2015 Jan;17(1):1-15
pubmed: 25622895
Blood. 2004 Apr 15;103(8):3175-84
pubmed: 15070700
J Natl Cancer Inst. 2013 Apr 3;105(7):452-8
pubmed: 23434901
Am J Pathol. 2003 May;162(5):1449-61
pubmed: 12707028
Clin Cancer Res. 2015 Jun 15;21(12):2802-10
pubmed: 25398450
Blood. 2004 Mar 15;103(6):2291-8
pubmed: 14592826
Blood. 2008 Oct 1;112(7):2935-45
pubmed: 18535198
PLoS One. 2015 May 14;10(5):e0125995
pubmed: 25973790
Cancer Res. 2005 Apr 15;65(8):3185-92
pubmed: 15833849
Tissue Eng Part C Methods. 2014 Aug;20(8):663-70
pubmed: 24294886
Am J Clin Oncol. 2004 Feb;27(1):8-13
pubmed: 14758126
Biomed Res Int. 2015;2015:901303
pubmed: 26273658
J Vis Exp. 2014 Mar 08;(85):
pubmed: 24637629
Oncoimmunology. 2018 Feb 22;7(6):e1434465
pubmed: 29872571
Genes Cancer. 2015 Nov;6(11-12):462-471
pubmed: 26807199
Int J Cancer. 2012 Mar 15;130(6):1459-69
pubmed: 21520044
Drug Deliv Transl Res. 2017 Aug;7(4):571-581
pubmed: 28290050
PLoS One. 2017 Jan 20;12(1):e0170384
pubmed: 28107433
Leukemia. 2015 Feb;29(2):483-90
pubmed: 24990616
Blood Res. 2017 Dec;52(4):293-299
pubmed: 29333406
Haematologica. 2011 Feb;96(2):284-90
pubmed: 21109694
Oncotarget. 2015 Apr 30;6(12):10460-72
pubmed: 25865044
Cancers (Basel). 2018 Jun 16;10(6):
pubmed: 29914181
Biomaterials. 2015 Dec;73:70-84
pubmed: 26402156
Nat Methods. 2014 Apr 29;11(5):483-8
pubmed: 24781320
Blood. 2011 Jan 20;117(3):890-901
pubmed: 20709908